Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: jack w garnes jr. who wrote (13460)	8/17/1998 9:28:00 AM
From: DaiS	Read Replies (1) \| Respond to of 23519

Jack, I think shorts can wait as long as they want....don't have to hurry and they can protect with calls. Scripts from Saszu: refills up, new down messages.yahoo.com@m2.yahoo.com Appears that muse stabilising at 2.5% of viagra. I'm becoming more and more convinced that the news are almost entirely from pool of regular users. Recruitment of new regulars is close to zero. It's all very well a doc on the thread saying they had someone new try muse yesterday, but this man has got to continue to use it. Why no new recruits, 1. Majority of US men wanting to try it have done so already. Their recruitment quite low because they weren't taught well or titrated on too low dose. 2. Viagra rejects will go back to as they were before. Docs not enthusiastic enough about muse to suggest it even if the patient asks for viagra alternative. Solution, Marketing partner promoting titration on higher doses. I think it is quite fascinating that the script numbers are not drifting downward, these regulars are real diehard muse enthusiasts. It would be interesting to know if caverject script numbers are now trending upwards....or perhaps not. As Vivus are so slow in announcing a partner I assume that they are counting on Bety's Q3 earnings estimates. DaiS